Go or no go? The year ends with Covid-19 vaccine approvals in sight
December promises big US decisions for Novartis, Astrazeneca and Fibrogen, as well as the FDA's first Covid-19 vaccine reviews.
Tide turns as 2017 IPOs ramp up
Biotechs raised $3.9bn in IPOs across 2017, signalling that investor interest in new issues has returned.